| 1 |
32914879 | ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. | 2020 Dec 15 |
1 |
| 2 |
31477684 | NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target. | 2019 Sep 2 |
1 |
| 3 |
27935326 | Role of CD56 in Normal Kidney Development and Wilms Tumorigenesis. | 2017 Feb |
2 |
| 4 |
28341109 | Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. | 2017 Jan |
1 |
| 5 |
24389179 | Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. | 2014 Jan 1 |
3 |
| 6 |
24492307 | Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. | 2014 Mar-Apr |
3 |
| 7 |
23798344 | Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. | 2013 Nov |
2 |